IMR Press / RCM / Special Issues / 1635407400313

Emergent Aspects of Familial Hypercholesterolemia Management

Submission deadline: 01 August 2022
Special Issue Editors
Justin P. V. Zachariah
Texas Children’s Hospital Baylor College of Medicine, Houston, TX 77030, USA
Interests: Pediatric cardiology; Preventive cardiology; Vascular medicine; Cholesterol/lipids; Blood pressure; Circulating biomarkers; Genomic; Metabolomic
Special Issue Information

Dear Colleagues,

 

Research into familial hypercholesterolemia (FH) is undergoing a remarkable evolution. Initially, FH was a Nobel Prize-winning archetype for Mendelian disorders that affect cardiovascular health. However, recent studies on FH have demonstrated a great deal of variety in the genetic substrate and in phenotypic presentation, with the interaction of these two factors determining the clinical outcome. The era of molecular medicine in cardiovascular medicine and elucidation of the pathways responsible for elevated low density lipoprotein cholesterol has led to an increased range of therapeutic tools against cardiovascular disease events in FH and beyond. This special issue will focus on emerging aspects of FH management relating to identification, therapy in general and special populations, confounders of elevated LDL-c, and new therapies in FH.

Familial Hypercholesterolemia: Emerging aspects
1. Genetic architecture of very elevated LDL-c: implications of genotype-phenotype discordance 
2. Screening advances for FH: population, cascade, reverse cascade
3. Management modifications in Special populations: Women, children, transgender
4. Standard therapeutics with statins and ezetimibe: state of the evidence
5. PCSK9 inhibition: FH standard care? At what cost?
6. Bempedoic Acid in high LDL-c: ranking management 
7. ANGPTL3 for FH: wrong pathway, right outcome?
8. Lomitapide and mipomersen: What, who, and when?
9. Mistaken identity: confounding from lipoprotein(a) and remnant LDL-c

 

Assoc. Prof. Justin P. V. Zachariah 

Guest Editor

Keywords
Familial hypercholesterolemia
Statin
Ezetimibe
Genomic medicine
LDL-c
PCKS9
ANGPTL3
ApoB
Lp(a)
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://jour.ipublishment.com/imr/access/login by registering and logging in to this website. Once you are registered, click here to start your submission Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted papers should be well formatted and use good English.

Back to top